We evaluated the effect of QVA149, a dual bronchodilator combining indacaterol and glycopyrronium, on direct patient-reported dyspnoea in patients with moderate-to-severe chronic obstructive pulmonary disease.<br><br>In this multicentre, blinded, double-dummy, three-period crossover study, 247 patients were randomised to once-daily QVA149 110/50 ?g, placebo or tiotropium 18 ?g. Superiority of QVA149 versus placebo (primary objective) and tiotropium (secondary objective) was assessed for improvement in dyspnoea via the self-administered computerised (SAC) version of the Baseline and Transition Dyspnoea Index after 6 weeks. Secondary end-points included lung function, rescue medication use and safety.<br><br>After 6 weeks, the SAC Transition Dyspnoea Index total score was significantly higher with QVA149 versus placebo (least squares mean (LSM) treatment difference 1.37, p<0.001) and tiotropium (LSM treatment difference 0.49, p=0.021). QVA149 provided significant improvements in lung function, with higher forced expiratory volume in 1 s area under the curve from 0–4 h post-dose versus placebo and tiotropium at day 1 and week 6 (all p<0.001). Rescue medication use was significantly lower with QVA149 versus placebo (p<0.001) and tiotropium (p=0.002). All treatments were well tolerated.<br><br>Once-daily QVA149 provided superior improvements in patient-reported dyspnoea and lung function versus placebo and tiotropium. These benefits were associated with improvements in other symptoms and reduced use of rescue medication.
Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD
The BLAZE study
Mahler, DA., Decramer, M., D'Urzo, A., Worth, H., White, T., Alagappan, VKT., Chen, H., Gallagher, N., Kulich, K., & Banerji, D. (2014). Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: The BLAZE study. European Respiratory Journal, 43(6), 1599-1609. https://doi.org/10.1183/09031936.00124013